TITLE

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

AUTHOR(S)
KUMAR, SHAJI K.; MIKHAEL, JOSEPH R.; BUADI, FRANCIS K.; DINGLI, DAVID; DISPENZIERI, ANGELA; FONSECA, RAFAEL; GERTZ, MORIE A.; GREIPP, PHILIP R.; HAYMAN, SUZANNE R.; KYLE, ROBERT A.; LACY, MARTHA Q.; LUST, JOHN A.; REEDER, CRAIG B.; ROY, VIVEK; RUSSELL, STEPHEN J.; SHORT, KRISTEN E. DETWEILER; STEWART, A. KEITH; WITZIG, THOMAS E.; ZELDENRUST, STEVEN R.; DALTON, ROBERT J.
PUB. DATE
December 2009
SOURCE
Mayo Clinic Proceedings;Dec2009, Vol. 84 Issue 12, p1095
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy, It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and Introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort--the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
ACCESSION #
45895951

 

Related Articles

  • Metatarsal Stress Fractures in Patients with Multiple Myeloma Treated with Long-Term Bisphosphonates: A Report of Six Cases. Waterman, Gabriel N.; Swift, Regina A.; Yellin, Ori; Jamshidinia, Kamran; Tamkin, James A.; Audell, Robert A.; Berenson, James R. // Journal of Bone & Joint Surgery, American Volume;9/21/2011, Vol. 93-A Issue 18, pe106-1 

    The article presents case studies of metatarsal stress fractures in patients with an incurable bone-marrow-based plasma-cell cancer, called multiple myeloma, that have been treated with long-term bisphosphonates. Topics include risk factors for stress factors, bisphosphonate therapy, and the...

  • Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population–Based Study. Tzeng, Huey-En; Lin, Cheng-Li; Tsai, Chun-Hao; Tang, Chih-Hsin; Hwang, Wen-Li; Cheng, Ya-Wen; Sung, Fung-Chang; Chung, Chi-Jung // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Studies involving second malignancies in patients with multiple myeloma are limited for the Asian population. Using data from population-based insurance claims, we assessed the risk of developing secondary malignancies after multiple myeloma, in particular hematologic malignancies. A...

  • The Relationships Among Physiologic Variables, Quality of Life, and Fatigue in Patients With Multiple Myeloma. Booker, Reanne; Olson, Karin; Pilarski, Linda M.; Noon, Joseph P.; Bahlis, Nizar J. // Oncology Nursing Forum;Mar2009, Vol. 36 Issue 2, p209 

    Purpose/Objectives: To investigate the relationships among physiologic variables, fatigue, and quality of life (QOL) in patients with multiple myeloma.Design: Cross-sectional, descriptive, exploratory.Setting: Outpatient ambulatory care clinics at a tertiary oncology center.Sample: 56 patients...

  • Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Vallabhapurapu, Subrahmanya D.; Noothi, Sunil K.; Pullum, Derek A.; Lawrie, Charles H.; Pallapati, Rachel; Potluri, Veena; Kuntzen, Christian; Khan, Sohaib; Plas, David R.; Orlowski, Robert Z.; Chesi, Marta; Kuehl, W. Michael; Bergsagel, P. Leif; Karin, Michael; Vallabhapurapu, Sivakumar // Scientific Reports;10/16/2015, p8428 

    Although transcriptional activation by NF-κB is well appreciated, physiological importance of transcriptional repression by NF-κB in cancer has remained elusive. Here we show that an HDAC4-RelB-p52 complex maintains repressive chromatin around proapoptotic genes Bim and BMF and regulates...

  • Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Cavo, M. // Leukemia (08876924);Aug2006, Vol. 20 Issue 8, p1341 

    Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter clinical trials in cancer patients. Based on results of preclinical studies showing that this novel agent directly inhibits the proliferation of myeloma cells, induces their apoptosis and abrogates paracrine tumor...

  • Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors-results from a Dutch population-based study. Oerlemans, Simone; Husson, Olga; Mols, Floortje; Poortmans, Philip; Roerdink, Henk; Daniels, Laurien; Creutzberg, Carien; Poll-Franse, Lonneke // Annals of Hematology;Oct2012, Vol. 91 Issue 10, p1587 

    To improve posttreatment care for (long-term) lymphoma survivors in the Netherlands, survivorship clinics are being developed. As information provision is an important aspect of survivorship care, our aim was to evaluate the current perceived level of and satisfaction with information received...

  • Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Palumbo, Antonio; Bertola, Alessandra; Faico, Patrizia; Rosato, Rosalba; Cavaiio, Federica; Giaccone, Luisa; Bringhen, Sara; Musto, Pellegrino; Pregno, Patrizia; Caravita, Tommaso; Ciccone, Giovannino; Boccadoro, Mario // Hematology Journal;2004, Vol. 5 Issue 4, p318 

    CONCLUSIONS:: As first salvage regimen, THAL-DEX was superior to CC, as second or third salvage regimen, it was equivalent to CC. THAL-DEX is not myelotoxic. It postpones the delivery of effective salvage chemotherapy. This might explain the survival benefit.The Hematology Journal (2004) 5,...

  • Abstract #11: The Disruptions to Cognition, Everyday Function, and Quality of Life in Oncology Patients: A Therapeutic Opportunity? Wesnes, Keith Andrew; Brooker, Helen; Edgar, Chris // Neurotherapeutics;Jul2010, Vol. 7 Issue 3, p331 

    Introduction: Patents with a variety of forms of cancer often report cognitive difficulties, and cognitive testing has confirmed the presence of impairments to attention and memory in several oncology populations. The purpose of this evaluation was to assess the profile of impairments across...

  • EXAMINING THE RELATIONSHIPS BETWEEN CLINICAL VARIABLES, QUALITY OF LIFE AND FATIGUE IN PATIENTS WITH MULTIPLE MYELOMA. Booker, Reane; Olson, Karin; Whyte, Darlen // Oncology Nursing Forum;Mar2007, Vol. 34 Issue 2, p568 

    Fatigue is one of the most commonly reported symptoms in patients with cancer and is almost certain to occur at some point along the illness trajectory in patients with multiple myeloma (MM). Fatigue remains a multifaceted symptom. Although most research has focused on the role of anemia, there...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics